2017 Was a Busy Year for State Imposition of Drug Manufacturer Price Disclosure Obligations and 2018 Isn’t Looking Much Better
State legislatures have been aggressive in taking on drug price increases. The author of this article discusses transparency disclosure requirement laws and what drug manufacturers should do now.
Although several bills were introduced in Congress and President Trump has complained that drug prices are way too high, during 2017, the federal government did not pass any law nor implement any policy requiring drug manufacturers to disclose information concerning price increases. As a result, state legislatures have stepped in to fill this void. Unlike Congress, state legislatures have been much more aggressive in taking on drug price increases.
To read the full article, please click here.
“2017 Was a Busy Year for State Imposition of Drug Manufacturer Price Disclosure Obligations and 2018 Isn’t Looking Much Better,” by Merle M. DeLancey Jr. was published in the April 2018 edition of Pratt’s Government Contracting Law Report (Vo. 4, No. 4), an A.S. Pratt Publication, LexisNexis. Reprinted with permission.
This article was first published in Blank Rome’s Government Contracts Navigator blog in January 2018.